INTRODUCTION
Haematopoietic cell transplant activity varies widely across world regions and between countries. 1 In 2012, 490% of transplants were done in three geographic regions, North America, Europe and Asia Pacific. 2, 3 The first reported transplants in Latin America were in the 1980s with activity increasing continuously thereafter. 4 However, despite episodic reports there is no comprehensive survey of Latin American transplant activity. [5] [6] [7] [8] The Latin American Bone Marrow Transplant Group (LABMT) was founded in 2011 under the auspices of the Worldwide Network for Blood and Marrow Transplantation (WBMT), a non-governmental organisation of the World Health Organization (WHO). The LABMT's aim is to foster cooperation and reporting amongst transplant centres in Latin America. This report focuses on estimating transplant activity and rates, identifying variables associated with these endpoints and detecting trends. Data from Latin America were compared with data from three geographic regions.
PATIENTS AND METHODS
Transplant teams were identified by a survey of Latin American haematology societies, transplant societies and transplant donor registries. Using this strategy, we identified 154 transplant centres that were invited to report transplants in [2009] [2010] [2011] [2012] . A total of 94 transplant teams accepted and sent data. We used a WBMT-developed questionnaire to collect data from responding centres (Supplementary Figure 1) . There was no independent investigation of transplant activity in each Latin American country and no comprehensive review of biomedical publications in diverse languages to identify discordances between reporting to us and publications. Variables ascertained in the WBMT template included disease, disease state, relationship between donor and recipient and graft-type. There was no auditing of transplant centres. Reports were supplemented by data from the WBMT for 28 Latin America WHO member states (Table 1) . Population data were obtained from the International Data Base Country Rankings of the US Census Bureau (https://www.census.gov/ population/international/data/idb/rank.php). As subject-level identifiers were not used, Ethical Committee approval was judged unnecessary.
We defined transplant rate as numbers of transplants per million inhabitants per country per year. Transplant team density was defined as number of transplant teams per million inhabitants per country or region. We compared these metrics with other variables including per capita gross national income (GNI), infant mortality rate, life expectancy (unadjusted), per capita health-care expenditure (HCE), HCE as a function of GNI, percent public-funded HCE, physician and nurse densities (per 1000 population), human development index, education level, numbers of public health facilities, country surface area, population density, population density of the capital city and percent population living in rural areas. 2012 data were obtained from the World Bank (www.worldbank.org) and WHO (www.who.int). Reporting countries were ranked by population, surface area, per capita GNI and HCE and physician density. To assess economic efficiency, we quantified transplant rates by per capita GNI and HCE.
Statistical analyses
The relationship between the 2012 transplant rate and socio-economic variables was analysed by multiple linear regression. The confidence interval was set to 95%, and the result of the analysis (fit) was evaluated using the R2 software. Table 1 ). The Latin American transplant team density is substantially lower than that of North America (6.2) and Europe (7.6). 3 Of the 11 519 first transplants, 7033 were autotransplants (61%) and 4486 were allotransplants ( Table 2 ). Autotransplant graft types included blood cells (N = 6854; 97%) and bone marrow cells (N = 178; 3%; Table 2 ). Reason for autotransplants were lympho-proliferative neoplasms including plasma cell myeloma (N = 6155; 88%), solid cancers (N = 490; 7%), leukaemias (N = 316; 5%) and non-neoplastic diseases (N = 150; 1%; Supplementary Table 1 ). Donors for allotransplants included an HLA-identical sibling (N = 3135; 70%), a HLA-matched unrelated donor (N = 1095; 24%) or a HLA-haplotype-matched relative (N = 229; 5%; Table 2 ). Graft types from family donors included blood cells (N = 1867; 59%), bone marrow cells (N = 1242; 40%) and umbilical cord blood cells (N = 53; 1%). Most transplants from Abbreviations: GNI/capita $ = gross national income/capita F$; HCE/capita $ = health-care expenditure/capita $; HSCT = haematopoietic stem cell transplant; NA = not available/not applicable; physician density = number of physicians/10 million inhabitants; team density = number of teams/10 million inhabitants.
RESULTS

Transplant
The next region for haematopoietic transplant progress G Jaimovich et al unrelated donors used umbilical cord blood cells (N = 447; 41%) followed by bone marrow cells (N = 402; 37%) and blood cells (N = 246; 22%). Reasons for allotransplants were leukaemias (N = 3134; 70%), non-neoplastic diseases (N = 1027; 23%) and lymphomas (N = 301; 7%; Supplementary Table 1) . Amongst leukaemia transplants, acute leukaemias were more common than chronic leukaemias, and persons in first remission were more common than were persons in other disease states. In total, 144 of 232 (62%) transplants for AML were in persons with advanced disease from HLA-matched unrelated donors. Transplants for CML were uncommon (N = 279); only 116 CML were in persons in 1st chronic phase.
Transplant activity in 2012
We analysed the 3263 first transplants done in 2012 in greater detail ( Figure 1 ). Transplants were for lympho-proliferative neoplasms (N = 1907; 59%), leukaemias (N = 957; 29%), non-neoplastic diseases (N = 259; 8%) and solid cancers (N = 140; 4%). Autotransplants (N = 2057; 63%) were more common than allotransplants (N = 1206; 37%). Most allotransplants (N = 900; 75%) were from relatives. In total, 107 of the unrelated donor transplants (35%) used umbilical cord blood cell grafts. Most countries reported doing auto-and allotransplants except Paraguay which reported only autotransplants (Table 3a) . Seven countries (Argentina, Brazil, Chile, Colombia, Ecuador, Mexico and Uruguay; Figure 1) .
Trends
Numbers of transplants increased by 30% from 2009 to 2012 (2517 vs 3263) with a 36% increase in autotransplants and a 20% increase in allotransplants (Supplementary Table 1 ). Increased autotransplants were predominately for plasma cell myeloma (39%). Increased allotransplants were predominately for acute leukaemias (33%). There was a slight decline in transplants for non-neoplastic disorders (Supplementary Table 1 ). Transplants of blood and bone marrow cells from unrelated donors increased by 115% and 28%, respectively (Table 2 ). There were also The next region for haematopoietic transplant progress G Jaimovich et al small increases in transplants of blood and bone marrow cells from HLA-matched relatives and from HLA-haplotype-mismatched related donors, of 12% and 124%, respectively (Table 2) .
Comparison with other regions 2012 transplant rates in Latin American countries are shown in Figure 2 . The Latin American region median transplant rate was 64 ranging from 14 in Paraguay to 300 in Uruguay (Table 3b ). Median transplant rates for auto and allotransplants were 40 (range, 8-215) and 24 (range, 0-88; Table 3a ). Median rates for related and unrelated donor transplants were 18 (range, 0-73) and 6 (range, 0-18; Table 3a ). Transplant rates in Latin America (median 60) were higher than in the Eastern Mediterranean (median 30) and Asia/Pacific (median 45) regions but lower than those in the American (median 482) and European (median 379) regions.
Transplant rates and socio-economic variables No transplants were reported from countries with o 3.3 million population or with a per capita GNI o$3400 USD (Table 1) . Argentina  111  106  5  26  51  12  162  38  465  110  627  149  Brasil  449  416  33  23  182  9  631  32  1062  53  1693  85  Chile  28  23  5  16  30  18  58  34  47  28  105  61  Colombia  95  83  12  21  14  3  109  24  162  36  271  60  Costa Rica  14  9  5  30  0  0  14  30  33  70  47  102  Ecuador  10  10  0  7  4  3  14  9  14  9  28  18  Mexico  106  82  24  9  21  2  127  11  97  8  224  19  Panama  11  11  0  31  0  0  11  31  27  75  38 The next region for haematopoietic transplant progress G Jaimovich et al
Per capita GNI and physician density were significantly associated whether there was reported transplant activity. Except for El Salvador, countries with 41 physician per 1000 inhabitants reported transplants. Per capita GNI (coefficient − 0.001; SE, 0.0004; P = 0.01), per capita HCE (coefficient 0.016; SE, 0.0056; P o0.01) and physician density (coefficient 3.447; SE, 1.4474; P = 0.03) were significantly associated with transplant rate. These three variables explained 90% of variations in transplant rates in reporting countries. There were no significant correlations between total population, population density, infant mortality rate, life expectancy, health expenditure as a function of GNI, percent public-funded HCE, physician and nurse densities (per 1000 population), human development index, education level, numbers of public health facilities, country surface area, population density, population density of the capital city and percent population living in rural areas. Per capita GNI and HCE and transplant rates varied substantially between reporting countries (see Supplementary Figure 2) . Consequently, the 12 reporting countries were ranked for descriptive analysis. Some countries had high economic indices and high transplant rates (Uruguay, Argentina), whereas others reported low-transplant rates despite high economic indices (Chile, Venezuela). Others had high transplant rates despite low-economic indices (Panama; Tables 3a , Table 3b ). Some countries had higher transplant rates as a function of per capita GNI (Uruguay, Panama and Costa Rica) and as a function of per capita HCE expenditures (Panama, Peru) than others had (Mexico, Venezuela; Table 3b ).
DISCUSSION
We report an analysis of haematopoietic cell transplant activity in Latin America. We found a 30% increase in transplant rate from 2009 to 2012, an increase greater than that reported in other geographic regions.
1 Nevertheless, the Latin America transplant rate is 5-8-fold lower than that in the North America and European regions, suggesting substantial growth potential. 1 Also, the proportion of allotransplants from HLA-matched unrelated donors was substantially less in Latin America compared with that in North America and European regions (25% vs 54%). This disparity likely results from smaller unrelated donor registries and less efficient search and sharing logistics in Latin America. Only four countries had unrelated donor registries (Brazil, Argentina, Mexico and Uruguay), and five countries reported no HLA-matched unrelated transplants. Also, median search time to transplant was long (for example, 6 months in Argentina) compromising use in persons with acute leukaemias. 9 Also, the proportion of bone marrow grafts was higher than in the North America and European regions. 1 This likely reflects economic considerations such as costs of apheresis devices and granulocyte-CSF (G-CSF). The higher proportion of transplants for bone marrow failure syndromes in Latin America (13%), a setting where use of bone marrow is preferred to blood cells, may also contribute to this disparity.
Several socio-economic factors are associated with transplant rates including per capita GNI, HCE and physician density. Similar data are reported for other geographic regions. 1, 2, 10 Other variables such as infant mortality rate, life expectancy or human development index were not reported. We estimate three variables, per capita GNI, per capita HCE and physician density, explain about 90% of the variance in transplant rates between reporting countries. The density of transplant teams in Latin America (1.8 per million population) is also substantially lower than in North America (6.2) and Europe (7.6) . 3 This disparity correlates with fewer transplants in Latin America. For example, Uruguay has the highest team transplant density and transplant rate, whereas Venezuela has the lowest of both. However, it is not possible to know whether less transplant team density causes fewer transplants, fewer transplants cause less transplant team density or an interaction. 10 Worldwide there is decreasing use of umbilical cord blood cell donors, especially in adults and increasing use of HLA-haplotype-matched relatives. There is a similar trend in our 2009-2013 data. We plan our next analysis in 2017 and will focus on this issue.
There are several important caveats to our conclusions. First, incompleteness. Not all invited transplant centres responded The next region for haematopoietic transplant progress G Jaimovich et al to the survey and two countries with known transplant activity did not respond. Other transplant centres may be unknown to us. Consequently, there may be under-reporting. Accuracy is another issue. We did not audit reporting centres for accuracy, consecutive reporting, data completeness or other variables. This could result in under-, over-and/or incorrect-reporting. Finally, we did not query transplant outcomes nor did we request subject-level data. These issues are targets of future LABMT reports. Despite these caveats, our analyses are an important starting point for developing transplant activities in Latin America.
